Ovid Therapeutics gains on bullish view at Wedbush [Seeking Alpha]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Seeking Alpha
Reiterating its view that small molecules hold promise against certain disease areas, such as epilepsy, the firm pointed to the company's lead asset, soticlestat, developed in partnership with Takeda ( NYSE: TAK ) and Ligand Pharmaceuticals ( NASDAQ: LGND Noting that OVID owns “multiple, unique assets” in the epilepsy space, the analysts issued an $8 per share target on the stock. Soticlestat is an oral medicine currently undergoing late-stage trials for epileptic conditions, Dravet syndrome, and Lennox-Gastaut syndrome. Citing pivotal data for soticlestat expected in September, Wedbush argued that “our estimates assign soticlestat credit, which offers a potential non-dilutive funding source for OVID.” Recommended For You More Trending News Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? [Yahoo! Finance]Yahoo! Finance
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy [Yahoo! Finance]Yahoo! Finance
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyBusiness Wire
- Travere gains on full FDA approval for kidney drug Filspari [Seeking Alpha]Seeking Alpha
- Ligand to Present at H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
LGND
Earnings
- 8/6/24 - Beat
LGND
Sec Filings
- 9/25/24 - Form 4
- 9/24/24 - Form 4
- 9/24/24 - Form 4
- LGND's page on the SEC website